AC Immune SA
NASDAQ:ACIU

Watchlist Manager
AC Immune SA Logo
AC Immune SA
NASDAQ:ACIU
Watchlist
Price: 3.15 USD -2.17% Market Closed
Market Cap: 311.7m USD

Operating Margin
AC Immune SA

-1 671.4%
Current
-818%
Average
-4.1%
Industry

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
-1 671.4%
=
Operating Profit
-73.1m
/
Revenue
4.4m

Operating Margin Across Competitors

Country Company Market Cap Operating
Margin
CH
AC Immune SA
NASDAQ:ACIU
316.3m USD
-1 671%
FR
Pharnext SCA
OTC:PNEXF
6T USD
-17 527%
US
Abbvie Inc
NYSE:ABBV
394.7B USD
33%
US
Amgen Inc
NASDAQ:AMGN
170.9B USD
34%
US
Gilead Sciences Inc
NASDAQ:GILD
149.5B USD
39%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
114.8B USD
39%
US
Epizyme Inc
F:EPE
94.1B EUR
-370%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
78.1B USD
28%
AU
CSL Ltd
ASX:CSL
89.1B AUD
26%
NL
argenx SE
XBRU:ARGX
45.9B EUR
22%
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
52.4B USD
8%
No Stocks Found

AC Immune SA
Glance View

Market Cap
316.3m USD
Industry
Biotechnology

AC Immune SA engages in the discovery and development of therapeutic and diagnostic products for neurodegenerative diseases. The company is headquartered in Lausanne, Vaud and currently employs 143 full-time employees. The company went IPO on 2016-09-23. The firm focuses on precision medicine for neurodegenerative diseases. The company designs, discovers and develops therapeutic, as well as diagnostic products for prevention, diagnosis and treatment of diseases caused by misfolding proteins. Its SupraAntigen and Morphomer technology platforms to create antibodies, small molecules and vaccines designed to address a broad range of neurodegenerative indications, such as Alzheimer's disease (AD). The firm's pipeline includes nine therapeutic product candidates with five in clinical trials, and three diagnostic candidates. Its lead product candidate is Crenezumab, a humanized and monoclonal anti-Abeta antibody for Alzheimer’s disease. The company has collaborations with pharmaceutical companies, including Roche/Genentech, Eli Lilly, Biogen, Janssen Pharmaceuticals, Nestle Institute of Health Sciences, Life Molecular Imaging (formerly Piramal Imaging) and Essex Bio-Technology.

ACIU Intrinsic Value
13.4 USD
Undervaluation 76%
Intrinsic Value
Price
What is Operating Margin?

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
-1 671.4%
=
Operating Profit
-73.1m
/
Revenue
4.4m
What is the Operating Margin of AC Immune SA?

Based on AC Immune SA's most recent financial statements, the company has Operating Margin of -1 671.4%.

Back to Top